Claims 1–4 present specific dosing protocols, combinations, and treatment sequences for BPC-157 and TB500 in acute and chronic injuries that have no support in published human clinical trials, registered clinical studies, or PubMed literature. These are internally consistent protocols but lack any empirical backing. Claim 5 (that chronic injuries involve cell migration) is conceptually sound and reflects established wound healing physiology. The creator has not cited specific studies for any of these claims, and no relevant human evidence was found to validate the proposed treatment regimens.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
BPC-157 Protocol Revealed #peptides #bpc157 #peptidetherapy
Video transcriptshow
Let me show you the exact protocol matrix that we've refined through thousands of treatments. So, after 10 years of seeing what works and what doesn't, and remember, there's no official human dosing in the research yet. Here's what our practitioners have found effective. Screenshot this, but work with your provider to customize it for you. So, we got acute injuries less than 2 weeks old. Start out…
Show full video transcript
aggressive BBC 157 500 micrograms daily plus TB500. You can work up to 2,000 micrograms daily. Your body's already in healing mode. You can amplify it. Chronic injuries over 6 months, different approach. Start with TB500 alone at 2,000 micrograms for 2 weeks. Then add BPC157 at 205 micrograms and increase to 500 after 2 weeks. Why chronic injuries need cell migration
Show lessClaim breakdown
5 claims“BPC-157 at 500 micrograms daily plus TB500 is effective for acute injuries less than 2 weeks old.”
No human clinical trials, registered studies, or PubMed literature were found for this specific dosing protocol or combination in acute injuries. While BPC-157 alone has preclinical support for tissue repair (Sikiric et al., tendon healing models), no evidence exists for the specific regimen, dosing, or combination with TB500 in human acute injury contexts.
“TB500 at 2,000 micrograms daily can be used to amplify the body's natural healing mode.”
No human clinical trials, registered studies, or PubMed literature were found for TB500 at this dosing or for the concept of 'amplifying healing mode.' TB500 (thymosin beta-4) has preclinical literature on cell migration and wound healing, but no human data exists to support this specific claim or dosing protocol.
“TB500 alone at 2,000 micrograms for 2 weeks is an effective initial approach for chronic injuries over 6 months.”
No human clinical trials, registered studies, or PubMed literature were found for TB500 at this dosing, duration, or application to chronic injuries. The claim includes a specific time frame (2 weeks) and injury timeline (>6 months old) for which no supporting evidence was located.
“BPC-157 at 205 micrograms, increasing to 500 micrograms after 2 weeks, can be added after initial TB500 treatment for chronic injuries.”
No human clinical trials, registered studies, or PubMed literature were found for this sequential dosing protocol, these specific dose escalations, or this combination approach in chronic injuries. The claim specifies precise microdose amounts and a particular treatment sequencing for which no supporting evidence exists.
“Chronic injuries need cell migration.”
This claim reflects a well-established principle in wound healing and tissue repair biology. While the two registered clinical trials retrieved (NCT07493889 on electrical stimulation for pressure injuries, NCT06007235 on amnion membranes for epidermolysis bullosa) do not directly address this mechanism, they operate within a framework where cell migration is a recognized component of chronic wound healing. The concept aligns with standard healing physiology documented across wound care literature.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error